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ABSTRACT
Background: Extracts of milk thistle (MT), Silybum marianum, have been used as medi-
cal remedies since the time of ancient Greece. Methotrexate is a potentially hepatotxic 
drug.
Objectives: To clarify the hepatoprotective effects of MT on methotrexate.
Materials and Methods: From January 2010 to April 2010, 30 male rats were recruited 
into three 10-rat subgroups in Tabriz University of Medical Sciences. Normal saline was 
injected intraperitoneally in the first group (A; the controls); intraperitoneal meth-
otrexate plus oral MT extract were administered to the second group (B) and intraperi-
toneal methotrexate alone was given to the third group (C). Pre- and post-interven-
tional measuring of serum parameters were carried out every 15 days. After six weeks, 
the rats were decapitated and histopathological evaluation of liver was done.
Results:  Serum  liver  enzymes  (AST,  ALT),  alkaline  phosphatase,  total  and  direct  bi-
lirubin, creatinine and BUN were measured on days 0, 15, 30, 45. They were significant-
ly higher in the group C, comparing with other two groups. Serum albumin was the 
least in group C animals as well. There were no significant differences between groups 
A and B. The mean±SD fibrosis score using semi-quantitative scoring system (SSS) was 
1.25±0.46, 1.40±0.52 and 6.70±0.82, in groups A, B and C, respectively (p<0.001).
Conclusions: MT extract can effectively prevent methotrexate-induced liver dysfunc-
tion and fibrosis in rats. 
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  Implication for health policy/practice/research/medical education:
Silymarine has effects on some pathophysiological processes of liver disorders. Doing animal studies help us to better understand-
ing these mechanisms.
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1. Background
Methotrexate (MTX) is a potent hepatotoxic agent. This 
drug  is  effective  in  various  cancers  and  immunologic 
disorders. It is used frequently in rheumatoid arthritis 
and  psoriasis.  This  drug  when  used  without  follow-
up has many side effects like hepatotoxicity and bone 
marrow suppression. MTX is accumulated in liver and is 
hepatotoxic. It seems that folic acid can reduce MTX side 
effects but it is not completely clarified. Clinicians use the 
drug frequently, so they would like to reduce its side effects 
especially its hepatotoxic effects (1). It was shown that 
milk thistle (Silybum marianum) has beneficial effects 
on hepatotoxicity (2). The objective of this study was to 
clarify the effect of MT on MTX-induced hepatotoicity in an 
animal model. In animal models, it has been shown that 
MT prevents atherosclerotic plaque formation in aorta. 
It has been shown that the cisplatin and cyclosporine Hepat Mon. 2011;11(6):464-468
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side  effects  reduced  when  MT  was  administered  in 
mice  (3,  4).  Reports  showed  that  silymarin  promote 
DNA polymerase, stabilize all membranes, inhibits free 
radicals and increases glutathione concentration, so it 
could protect liver from hepatotoxic agents. Silibinin is 
able to stimulate the activity of the DNA-dependent RNA 
polymerase I and causes an increase in rRNA synthesis. 
It accelerates formation of intact rRNA polymerase with 
resultant  formation  of  new  hepatocytes  (5).  Silymarin 
inhibits lipoxygenase cycle, leukotrienes and free radicals 
formation in mice Kupffer cells, so inflammation may 
be reduced (6). Treatment with MT has been usual since 
2000 years ago and it is mentioned as a hepatoprotective 
agent  (7).  MT  is  found  in  many  areas  all  around  the 
world and is cultured in North and South parts of Iran. 
This  drug  is  absorbed  via  the  gastrointestinal  tract; 
the  maximum  blood  level  is  reached  after  2-4  hours. 
The half-life of the drug is six hours. About 80% of MT is 
secreted into the bile and its bioavailability depends on 
its formulation (8). Sylibin is the most effective agents in 
MT and is known as an antioxidant and hepatoprotective 
agent. Its concentration in bile is 60 times greater than 
the blood. Silymarin has various cardiovascular effects 
(9). Silymarin inhibits liver enzymes like gamaglutamil 
transpeptidase  (GGT),  alanine  transaminase  (ALT)  and 
aspartate transaminase (AST) in rats (5). This drug blocks 
hepatic fibrosis due to biliary obstruction in mice. In one 
study a formulation of silymarin extract (Legalon) was 
used in 2637 patients with chronic liver disease for eight 
weeks when the liver enzymes remarkably decreased in 
88% of patients. Side effects were seen in lesser than 1% 
of patients (10). Silymarin is widely used in poisoning 
with Amanita fungus and reduces mortality significantly 
(60%–80%).  The  effects  of  silymarin  on  alcoholic  liver 
damages are controversial, but in a controlled double 
blind clinical trial this drug could improve liver enzyme 
level and histopathologic liver features after four weeks 
in alcoholic hepatotoxicity (11). In one study, silymarin 
could  reduce  mortality  in  patients  with  alcoholic 
cirrhosis  after  four  years.  In  another  study,  however, 
silymarin could not reduce hepatic mortality in cirrhotic 
patients (12). Silymarin effects on hepatic damages due to 
hepatitis are also controversial. In a double blind clinical 
trial, 20 patients with chronic active hepatitis received 
240 mg of silybin complex (silipide) two times a day for 
seven days; the GGT level reduced significantly (13). In 
another  study,  29  patients  with  viral  hepatitis  treated 
with silymarin and 28 patients received placebo; serum 
bilirubin, AST and ALT levels significantly reduced in the 
treatment group but in another study with 151 patients 
with viral hepatitis this drug could not improve their 
clinical condition (14). Silymarin has other therapeutic 
effects. It reduces LDL cholesterol level and atherosclerotic 
plaque formation in rabbit and mice (15). This agent has 
some mild side effects like allergic reactions in sensitive 
patients.  In  animal  models,  silymarin  in  higher  doses 
has not any side effects. Long-term use of this drug was 
safe. Silymarin also is safe in pregnancy, lactation and 
children (12).
2. Objectives
This  study  tries  to  determine  the  hepatoprotective 
effects of MT on MTX-induced hepatotoxicity.
3. Materials and Methods
In  an  experimental  study,  30  rats  (weigh  250-300  g) 
were used. The rats were in animal house for one week 
and had access to water and food ad libitum. Temperature 
was kept at 37 °C. After one week, the rats were randomly 
Group Cr (mg/dL) BUN (mg/dL) ALT (IU/L) AST (IU/L) BIL (mg/dL) BILD (mg/dL) Alb (g/dL) ALP (IU/L)
Group A
1 (Day 0)
2 (Day 15)
3 (Day 30)
4(Day 45)
0.56 ± 0.06
0.56 ± 0.5
0.54 ± 0.5
0.54 ± 0.08
11.33 ± 1.12
11.40 ± 1.17
11.50 ± 1.26
11.11 ± 1.00
32.40 ± 7.38
31.70 ± 6.18
32.40 ± 7.38
33.30 ± 3.23
119.70 ± 69.91
99.60 ± 9.78
98.60 ± 8.30
95.70 ± 8.43
0.56 ± 0.86
0.28 ± 0.08
0.28 ± 0.08
0.27 ± 0.12
0.40 ± 0.70
0.14 ± 0.03
0.14 ± 0.04
0.14 ± 0.02
3.79 ± 025
3.91 ± 0.26
3.79 ± 0.25
3.73 ± 0.20
120.00 ± 4366
110.80±34.10
110.10±33.87
99.60 ± 7.42
Group B
1 (Day 0)
2 (Day 15)
3 (Day 30)
4(Day 45)
0.55 ± 005
0.57 ± 0.05
0.56 ± 0.05
0.57 ± 0.05
11.41 ± 1.16
11.72 ± 1.02
11.52 ± 1.15
11.41 ± 1.16
32.40 ± 7.38
34.00 ± 4.16
34.00 ± 4.16
34.90 ± 4.40
111.00 ± 52.37
86.80 ± 8.01
85.50 ± 5.23
85.60 ± 4.81
0.28 ± 010
0.30 ± 0.11
0.31 ± 0.07
0.27 ± 0.09
0.15 ± 0.02
0.13 ± 0.03
0.14 ± 0.03
0.14 ± 0.02
3.79 ± 0.25
3.79 ± 0.25
3.79 ± 0.25
3.79 ± 0.25
105.10 ± 1513
126.90 ± 40.42
117.30 ± 31.61
105.30 ± 13.87
Group C
1 (Day 0)
2 (Day 15)
3 (Day 30)
4(Day 45)
0.56 ± 005
0.60 ± 0.04
0.63 ± 0.07
0.72 ± 0.10
11.52 ± 1.15
12.41 ± 1.94
16.50 ± 1.43
16.90 ± 1.91
32.40 ± 7.38
75.60 ± 17.04
183.30 ± 43.46
596.00 ± 101.21
114.80 ± 50.63
187.80 ± 37.54
362.90 ± 57.51
800.70 ± 86.99
0.56 ± 086
1.58 ± 0.27
2.31 ± 0.64
2.91 ± 0.63
0.42 ± 0.74
1.23 ± 0.27
1.88 ± 0.68
2.53 ± 0.58
3.79 ± 025
3.69 ± 0.22
3.05 ± 0.21
2.80 ± 0.21
129.40 ± 6224
128.00 ± 14.17
139.00 ± 15.65
147.60 ± 24.67
P value < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 0.01
Table 1. Mean±SD of measured biochemical parameters in the studied groupsHepat Mon. 2011;11(6):464-468
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divided into three equal groups: Group A rats received 
normal saline (600 mg/kg); group B received MTX (100 μg/
kg) intraperitoneally and silymarin (600 mg/kg) orally; 
group C rats received MTX (100 μg/kg) intraperitoneally 
alone. We used 1 mL of MTX (1000 mg/10 mL) and diluted 
it in 99 mL of normal saline and then 1 mL of product 
was diluted in 9 mL of normal saline (100 μg/mL MTX). 
It was injected by insulin syringes. MT was administered 
orally by a special syringe for rats after four hours. This 
study  was  done  in  Education  Development  Center  of 
Tabriz University of Medical Sciences, Tabriz, Iran. The 
study was conducted under supervision of a zoologist 
and pharmacist, professional in these kinds of animal 
studies.
MT  seeds  were  obtained  from  different  areas  of 
Aras  river  in  East  Azarbayjan,  North-West  of  Iran.  In 
pharmacognosy  laboratory  of  pharmacy  faculty,  dry 
seeds  were  milled  and  processed  with  hexane;  the 
silymarin  and  its  flavonolignan  were  extracted  using 
succilating  method.  After  solvent  evaporation,  the 
amount  of  the  total  flavonolignans  of  silymarin  was 
measured  by  spectrophotometry.  Extracted  materials 
were  fractionated,  using  SPE  (sep-pak)  cartridges  and 
methanol-water  mixture.  Solvent  of  the  obtained 
fractions was evaporated and the product was used in 
this study. Tabriz University of Medical Sciences Ethical 
Committee  approved  this  study.  All  animals  received 
humane care according to the criteria outlined in the   
“Guide  for  the  Care  and  Use  of  Laboratory  Animals”   
prepared  by  the  National  Academy  of  Sciences  and 
published  by  the  National  Institutes  of  Health  (NIH 
publication 86-23 revised 1985). For biochemical studies, 
blood samples were taken before the intervention and 15, 
30 and 45 days post-intervention. Serum samples were 
examined for alanine aminotransferase (ALT), aspartate 
aminotransferase  (AST),  alkalin  phosphatase  (ALP), 
blood  urea  nitrogen  (BUN),  creatinine  (Cr),  bilirubin 
(Bil), and albumin (Alb). Every morning (8–9 am), MTX 
was injected; MT was given orally by special syringe four 
hours later. Six weeks after intervention, rats were killed, 
their livers were fixed in 10% formalin and studied for 
histopathologic changes. The samples were scored using 
a semi-quantitative scoring system (SSS) (16) as below:
• < 2: normal;
• 2–6: mild fibrosis;
• 6–10: moderate fibrosis;
• > 10: sever fibrosis;
The  data  were  analyzed  by  SPSS®  for  Windows®  ver 
17. The continuous variables were first tested to see if 
they  were  distributed  normally.  Descriptive  statistics, 
including  the  mean  and  standard  deviation  (SD)  was 
calculated for all variables. One-way ANOVA or Kruskal-
Wallis test was used to compare means of three or more 
groups. Pairwise comparisons of the study groups were 
performed using Tukey’s HSD and Mann-Whitney U test 
as post hoc tests. A p < 0.05 was considered statistically 
significant.
4. Results
Biochemical  parameters  were  measured  before 
the  intervention,  and  15,  30,  and  45  days  after  the 
intervention.  The  creatinine  level  was  significantly 
different among all the studied groups (p < 0.001) but 
groups  A  and  B.  Therefore,  creatinine  level  was  lower 
in  patients  treated  with  MT  (Table  1).  BUN  was  also 
significantly  different  among  the  studied  groups  (p 
< 0.001). BUN level was better in rats treated with MT 
(Table 1). ALT was also significantly different among all 
(p < 0.001) but groups A and B (p = 0.211). ALT level was 
lower in group B (Table 1). AST level was also significantly 
different among all studied groups (p < 0.001) (Table 1). 
Total bilirubin level was significantly different among all 
(p < 0.001) but groups A and B was not remarkable. Total 
bilirubin level was lower in rats treated with MT (Table 1). 
Direct bilirubin level was significantly different among 
all studied groups (p < 0.001) (Table 1).
Albumin  level  was  significantly  different  among  the 
studied groups (p < 0.001) (Table 1). Bilirubin was lower 
and albumin was higher in group B rats. ALP was also 
significant  among  the  studied  groups  (p  =  0.01).  The 
difference between groups A and C was significant (p = 
0.01) but it was not among other paired groups (Table 
1).  It  must  be  emphasized  that  we  did  not  measure 
prothrombin time. The mean ± SD SSS score was 1.25 ± 
0.49 in group A, 1.40 ± 0.52 in group B and 6.70 ± 0.82 
in  group  C  rats.  The  score  was  significantly  higher  in 
group  C  (p  <  0.001)—fibrosis  was  more  severe  in  rats 
exposed to MTX without MT extract. The mean SSS score 
was  significantly  different  among  the  studied  groups. 
Difference between paired groups was only significant 
between groups A and C (p < 0.001) and also groups B 
and C (p < 0.001) (Figure 1).
5. Discussion
In this study protective effects of MT on MTX-induced 
liver  damage  in  rats  was  investigated.  We  found  that 
Figure 1. Error bar chart of SSS scores at the end of the study.Hepat Mon. 2011;11(6):464-468
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the  mean  levels  of  ALT,  AST,  ALP  and  bilirubin  in  rats 
that received MTX plus MT were significantly lower than 
those animals received only MTX. Difference of studied 
parameters  between  MTX  plus  MT  and  control  group 
(that received only normal saline) was not significant. Up 
to now, various studies revealed protective effects of MT 
in hepatic damages (17). In these studies, it was shown 
that extract of MT reduced treatment period of acute and 
chronic  hepatitis  (18).  Protective  effects  of  MT  in  fatty 
liver, cirrhosis, viral hepatitis, ischemic liver damage and 
cancer was shown previously (19). In our study, also SSS 
score in MTX plus MT group was significantly lower than 
that in MTX group which reflected protective effects of 
MT. Buzzelli and colleagues showed that administration 
of MT extract to 20 patients with chronic active hepatitis 
reduced serum liver enzymes, ALP and bilirubin levels 
after seven weeks (20). In our study, liver enzymes and 
bilirubin were reduced in rats received MT. Giese showed 
that MT extract has antihepatitic effects (21). Dhiman also 
emphasized protective effects of MT on hepatic disease 
(22). Mayer revealed protective and curative effects of MT 
on viral hepatitis (23). Rambaldi and colleagues showed 
these protective and curative effects in viral and alcoholic 
hepatitis  (24).  Jacobs  et  al.  emphasized  the  protective 
effects  of  MT  extracts  in  hepatic  disease  (25).  Other 
investigators  like  Gassileth  (2008),  Ross  (2008),  Raina 
(2008), and Ramakrishnan (2008), also emphasized the 
efficacy of MT extract on liver disease and its safety (7, 26-
28). Protective mechanisms of MT extract in liver disease 
are mentioned in different studies (29-31). Some of them 
are antioxidant, anti- lipid peroxidase, anti-fibrinolytic, 
anti-inflammatory  and  immunomodulatory  effects, 
induction  of  cell  formation,  glutathione  inhibition, 
reduction  of  leukotrienes,  reduction  of  tumor 
promoters and P450 inhibition. We found that the mean 
BUN and creatinine level were lower in the group that 
received MT extract. So reno-protective effects are also 
proposed  (32).  In  animal  studies,  this  drug  prevented 
atherosclerotic plaque formation in aorta (33). Previous 
studies revealed that silymarin prevents acetaminophen 
and  tetrachloromethane  hepatotoxic  effects  (22). 
Reports showed that MT may promote DNA polymerase, 
stabilize all membrane, inhibit free radicals and increase 
glutathione  concentration,  so  it  protects  liver  against 
hepatotoxic agents (34). Promotion of DNA polymerase 
leads to rRNA synthesis and hepatocellular regeneration. 
By  increasing  glutathione  concentration,  it  stabilizes 
superoxide dismutase and glutathione peroxidase (18). 
Different animal studies showed that silymarin protects 
hepatocytes  against  viruses,  chemical  agents,  fungal 
toxins  and  alcohol-premedication.  This  drug  protects 
animals against fatal effects of Amanita toxins (12, 35). 
Silymarin premedication prevents hepatotoxic effects of 
halothane,  thallium  tetrachloride  and  acetaminophen 
in animal studies (7). Silymarin inhibits liver enzymes 
like  gamma-glutamyl  transpeptidase  (GGT),  ALT  and 
AST  in  rats  (36).  In  one  study,  Silymarin  could  reduce 
mortality in patients with alcoholic cirrhosis after four 
years.  On  the  other  hand,  in  another  study,  silymarin 
could not reduce hepatic mortality in cirrhotic patients 
(35). In our study it was shown that MT extract protects 
liver against MTX hepatotoxic effects. Liver enzymes (AST, 
ALT and ALP), bilirubin and albumin remain unchanged. 
Also MT extract prevents kidney injury due to MTX in rat. 
BUN and creatinine levels remain unchanged. MT extract 
significantly prevents liver damage due to MTX in rat, 
so similar human studies are required. Studies on the 
effect of MT extracts on drug-induced kidney injury are 
therefore warranted. Similar results would justify use of 
MT extract in patients receiving MTX as a prophylactic 
agent against hepatic side effects.
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